European Journal of Clinical Pharmacology

, Volume 9, Issue 1, pp 57–61 | Cite as

On the fate of furosemide in man

  • B. Beermann
  • E. Dalén
  • B. Lindström
  • A. Rosén
Originals

Summary

35S-furosemide was administered orally (n=7) or i.v. (n=2) to healthy subjects. The average gastrointestinal uptake estimated by comparison of the urinary recovery of label and the areas under the plasma curves after the two routes of administration was 65%. The half life of radioactivity in the plasma after oral35S-furosemide was 90 ± 17 min (estimated on the slope between 2 and 6 h); the corresponding figure after35S-furosemide i.v. was 47–53 min (slope 0.5–4 h). There was probably a slower phase after 4–6 h. Fractionation of labelled material in urine from two subjects demonstrated that approximately two thirds of the label recovered at 24 h had the same chromatographic properties as furosemide. A major part of the metabolite(s) was probably furosemide glucuronide. There was no evidence that 4-chloro-5-sulfamoylanthranilic acid was formed in man. The total urinary recovery of label (5–7 d) after oral and intravenous administration was 55.1±3.2 (mean±SD) and 82–84%, respectively. After35S-furosemide i.v., 6–9% of the label was recovered in faeces, and it could not be accounted for solely by biliary excretion of furosemide.

Key words

Furosemide gastrointestinal absorption diuretics glucuronides pharmacokinetics metabolism 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beermann B., Hellström, K., Rosén, A.: Gastrointestinal absorption of certain anti-cholinergic drugs. Europ. J. clin. Pharmacol.5, 87–92 (1972)Google Scholar
  2. Beermann, B.: On the fate of orally administered3H-lanatoside C in man. Europ. J. clin. Pharmacol.5, 11–18 (1972)Google Scholar
  3. Bray, G.B.: A simple efficient liquid scintillator for counting aqueous solutions in liquid scintillation counter. Ann. Biochem. exp. Med.1, 279–285 (1960)Google Scholar
  4. Calesnick, B., Christensen, J.A., Richter, M.: Absorption and excretion of furosemide-S35 in human subjects (31391). Proc. Soc. exp. Biol. (N.Y.)123, 17–22 (1966)Google Scholar
  5. Cutler, R.E., Forrey, A.W., Christopher, T.B., Kompel, B.M.: Pharmacokinetics of furosemide in normal subjects and functionally anephric patients. Clin. Pharmacol. Ther.15, 588–596 (1974)Google Scholar
  6. Hajdù P., Häussler, A.: Untersuchungen mit dem Salidiureticum 4-chlor-N (2-furylmethyl)-5-sulfamyl-antranilsäure. Arzneimittel-Forsch.14, 709–710 (1964)Google Scholar
  7. Häussler, A., Wicha, H.: Untersuchungen mit dem Salidiureticum 4-Chlor-N-(2-furylmethyl)-5-sulfamyl-anthranilsäure. Arzneimittel-Forsch.15, 81–83 (1965)Google Scholar
  8. Kelly, M.R., Cutler, R.E., Forrey, A.W., Kimpel, B.M.: Pharmacokinetics of orally administered furosemide. Clin. Pharmacol. Ther.15, 178–186 (1974)Google Scholar
  9. Kindt, H., Schmid, E.: Über die Harnausscheidung von Furosemid bei Gesunden und Kranken mit Lebercirrhose. Pharmacol. Clin.2, 221–226 (1970)Google Scholar
  10. Lindström, B., Molander, M.: Gaschromatographic determination of furosemide in plasma using an extractive alkylation technique and an electron capture detector. J. Chromatogr.101, 219–221 (1974)Google Scholar
  11. Rupp, W., Hajdú, P.: Pharmacokinetics and pharmacodynamics of a diuretic agent. In: Pharmacological and clinical significance of pharmacokinetics. (Ed. H.J. Dengler) pp. 105–111, Stuttgart-New York: F.K. Schattauer Verlag 1970Google Scholar
  12. Rupp, W., Heidland, A., Hajdù, P. and Neuhans, G.: Pharmakokinetik von Furosemid bei normaler und eingeschränkter Nierenfunktion. In 4. Freiburger Tagung über Nephrologie 1970, Stuttgart: Thieme, pp. 207–213, 1970Google Scholar
  13. Rupp, W., Zapf, R.M.: Beispiele zur Phase I: Diuretika. Arzneimittel-Forsch.23, 1665–1668 (1973)Google Scholar

Copyright information

© Springer-Verlag 1975

Authors and Affiliations

  • B. Beermann
    • 1
  • E. Dalén
    • 1
  • B. Lindström
    • 1
  • A. Rosén
    • 1
  1. 1.Department of Medicine and the Clinical Pharmacology Laboratory, Serafimerlasarettet, and Division of Clinical Drug Trials, Department of DrugsNational Board of Health and WelfareStockholmSweden

Personalised recommendations